Novo Nordisk clinical trials are the talk of the medical community as the 2026 European Congress on Obesity (ECO) approaches. From 12–15 May in Istanbul, Turkey, the pharmaceutical giant will unveil data from 52 different abstracts, marking a pivotal moment for the future of metabolic health. This massive data dump aims to clarify how higher doses of semaglutide and new combination therapies like CagriSema can further push the boundaries of weight management.
The focus of these Novo Nordisk clinical trials extends beyond simple weight loss; the research dives into cardiovascular health, physical function, and the specific needs of women navigating the complexities of menopause.
High-Dose Wegovy® and Oral Innovation
Central to the presentation is the STEP UP trial, which examines a 7.2 mg dose of semaglutide. For patients who plateau on standard dosages, these Novo Nordisk clinical trials suggest that a higher ceiling may provide the necessary metabolic nudge to achieve sustained, long-term results.
Wegovy® (Semaglutide) Pipeline & Real-World Data
| Trial / Study | Dosage | Key Analysis Point | Presentation Timing |
| STEP UP | Semaglutide 7.2 mg | Body Weight Loss & Menopausal Status | Tuesday, 12 May |
| OASIS 4 | Oral Semaglutide 25 mg | Physical Function Improvements | Poster Session |
| ORION | Oral Semaglutide | Comparison vs. Orforglipron | Friday, 15 May |
| SELECT | Semaglutide 2.4 mg | MACE in Menopausal Women | Tuesday, 12 May |
Learn More: Novo Nordisk Announces Significant Price Reduction on Wegovy & Ozempic
Gilead Accelerates Global Access Strategy for Gilead Once-Yearly Lenacapavir in HIV Prevention Push
Gilead Sciences accelerates global access planning for investigational once-yearly lenacapavir, expanding royalty-free generic licensing across 120 high-incidence countries alongside Phase 3 PURPOSE 365 trials. […]
Novo – Anthropic Claude Science Partnership Targets Faster Drug Discovery
Novo and Anthropic announced a September 16, 2026 collaboration pairing Claude Science with Novo's R&D teams to tackle drug discovery challenges and strengthen AI-driven software […]
Amgen IMDELLTRA Monitoring Time Cut to 6-8 Hours as FDA Approves Label Update for ES-SCLC
The FDA has approved a label update cutting Amgen IMDELLTRA monitoring time for the first two doses from 22-24 hours to 6-8 hours, a change […]
Next-Generation Therapy: The Impact of CagriSema
The scientific leadership of the company is most evident in the results of the REDEFINE program. These Novo Nordisk clinical trials evaluate CagriSema, a combination of semaglutide and the long-acting amylin analogue, cagrilintide. By targeting multiple satiety pathways simultaneously, CagriSema represents the “next-gen” of obesity treatment.
The scientific leadership of the company is most evident in the results of the REDEFINE program. These Novo Nordisk clinical trials evaluate CagriSema, a combination of semaglutide and the long-acting amylin analogue, cagrilintide. By targeting multiple satiety pathways simultaneously, CagriSema represents the “next-gen” of obesity treatment.
